ArticleBMC medical imaging2025
Exploring the relationships between CT and pathological characteristics and gene mutations in neoplastic ground glass nodules.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeoplastic ground glass nodules (GGNs) are relatively indolent tumors, with slow progression in invasiveness and computed tomography (CT) features. This study aimed to explore the correlation between pathological and CT characteristics and gene mutations in neoplastic GGNs.
methodsWe retrospectively analyzed 1,348 neoplastic GGNs from January 2019 to November 2022, including 290 adenocarcinomas in situ (AIS), 448 microinvasive adenocarcinomas (MIA), and 610 invasive adenocarcinomas (IAC). The correlations between patients' characteristics, pathological subtypes and grades, CT features, changes in follow-up, and gene mutations were analyzed.
resultsSolid component (odds ratio [OR] = 1.493; P = 0.014), larger size (OR = 1.049; P = 0.006), ill-defined boundary (OR = 1.368; P = 0.027), and lobulation sign (OR = 1.824; P = 0.001) were revealed as independent CT predictors of gene mutation. From AIS to IAC, the epidermal growth factor receptor (EGFR) mutation rate significantly increased (P < 0.01), while the kirsten rat sarcoma viral oncogene (KRAS) and the anaplastic lymphoma kinase (ALK) mutation rates significantly decreased (P < 0.05). Among IACs, mutation rate was the highest in the intermediate-grade ones (P < 0.05). Gene mutations were more frequently detected in nodules showing changes during follow-up (76.3% vs. 61.1%, P = 0.02), especially in those with more than 2-year follow-up (77.1% vs. 43.7%, P = 0.023). However, the specific changes were not associated with gene mutations (P = 0.273).
conclusionsGene mutations in neoplastic GGNs were associated with CT features, pathological subtypes and grades, and changes observed during long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.